IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global market opportunity across 4 product groups projected to double to […]
Coronary/Structural Heart
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending […]
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – – Presentation of comprehensive data at a key medical conference in the first quarter of 2023 – ANN ARBOR, […]
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
— Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 — — Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe — DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc […]
CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt […]
Ultromics receives FDA Clearance for its Breakthrough Device EchoGo Heart Failure: An AI-based platform that enables precision detection of heart failure with preserved ejection fraction
EchoGo® Heart Failure revolutionizes the detection of HFpEF – the biggest unmet need in cardiovascular medicine.1 OXFORD, England, Dec. 6, 2022 /PRNewswire/ — Ultromics’ EchoGo® Heart Failure, an AI solution for echocardiography with the potential to revolutionize the diagnosis of heart failure with preserved ejection fraction (HFpEF), has received US Food and Drug […]
Henry Ford Health to Lead First-of-its-Kind National Trial for Innovative Heart Device
Clinical trial will enroll more than 3,000 patients across 75 participating hospitals in U.S. DETROIT, Dec. 6, 2022 /PRNewswire/ — Henry Ford Health will be spearheading a multi-center, first-of-its-kind national clinical trial dubbed the “CORRAL-AF IDE” study for an innovative left atrial appendage occlusion device known as the LAmbre™ Plus Left Atrial […]
BaleDoneen Method Study Identifies New Strategy to Prevent Heart Attacks, Strokes and Chronic Illness: Stopping Oxidative Stress
SPOKANE, Wash., Dec. 6, 2022 /PRNewswire/ — Atherosclerosis starts when cholesterol becomes trapped in the artery wall, sparking inflammation that could lead to a heart attack, stroke, or other chronic illnesses. The most common trigger is oxidative stress, which has been implicated in many chronic diseases, according to new peer-reviewed research published Frontiers […]
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today […]
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
Approval marks second clinical trial approved by FDA this year for Company’s NK1R+ MSC platform Allogeneic CardiALLO therapy for heart failure to complement autologous cell therapy currently enrolling in Phase III CardiAMP Heart Failure clinical trial SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment […]
Recent
FDA APPROVES LABELING UPDATE REFLECTING EVIDENCE IN RUPTURED AAA FOR GORE® EXCLUDER® AAA ENDOPROSTHESIS AND GORE® EXCLUDER® CONFORMABLE AAA ENDOPROSTHESIS
The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?
New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
Popular
- No commented posts yet